n Cardiovascular Journal of South Africa - Cardio news

Volume 14, Issue 5
  • ISSN : 1680-0745



Extracted from text ... 288 Unsurpassed glycaemic control made simple The Pharmaceutical Division of Merck (Pty) Ltd, marketers of the most prescribed oral anti-diabetic agent, Glucophage, proudly announces the launch of the first fixed-combination drug therapy for unsurpassed glycaemic control - Glucovance(r). Glucovance(r) is a new treatment for improving blood glucose control for patients with type 2 diabetes who are inadequately controlled by existing oral treatments. Glucovance(r) offers unsurpassed glycaemic control in a single tablet. Glucovance(r), the first fixed-combination drug therapy for glycaemic control, brings together two tried and tested ingredients, metformin and glibenclamide, in one tablet. Both of these have been the mainstay of ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error